Targeting host tyrosine kinase receptor EphA2 signaling via small-molecule ALW-II-41-27 inhibits macrophage pro-inflammatory signaling responses to Pneumocystis carinii β-glucans
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.00811-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Theodore J Kottom und 2 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Medicine and Biochemistry, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Pneumocystis carinii, beta-Glucans, Receptor, EphA2, Pneumonia, Pneumocystis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIAID NIH HHS, HHS | National Institutes of Health.
Abstract (Originalsprache)
Pneumocystis jirovecii, the fungus that causes Pneumocystis jirovecii pneumonia (PJP), is a leading cause of morbidity and mortality in immunocompromised individuals. We have previously shown that lung epithelial cells can bind Pneumocystis spp. β-glucans via the EphA2 receptor, resulting in activation and release of proinflammatory cytokines. Herein, we show that in vivo Pneumocystis spp. β-glucans activation of the inflammatory signaling cascade in macrophages can be pharmacodynamically inhibited with the EphA2 receptor small-molecule inhibitor ALW-II-41-27. In vitro , when ALW-II-41-27 is administrated via intraperitoneal to mice prior to the administration of highly proinflammatory Saccharomyces cerevisiae β-glucans in the lung, a significant reduction in TNF-alpha release was noted in the ALW-II-41-27 pre-treated group. Taken together, our data suggest that targeting host lung macrophage activation via EphA2 receptor-fungal β-glucans interactions with ALW-II-41-27 or other EphA2 receptor kinase targeting inhibitors might be an attractive and viable strategy to reduce detrimental lung inflammation associated with PJP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Medicine and Biochemistry, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
- Thoracic Diseases Research Unit, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
ORCID-Profile: Theodore J Kottom, Andrew H Limper
Förderung
- NHLBI NIH HHS
- NIAID NIH HHS
- HHS | National Institutes of Health
Zitieren
APA
Kottom, T. J., Carmona, E. M., & Limper, A. H. (2024). Targeting host tyrosine kinase receptor EphA2 signaling via small-molecule ALW-II-41-27 inhibits macrophage pro-inflammatory signaling responses to Pneumocystis carinii β-glucans. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00811-23
Vancouver
Kottom TJ, Carmona EM, Limper AH. Targeting host tyrosine kinase receptor EphA2 signaling via small-molecule ALW-II-41-27 inhibits macrophage pro-inflammatory signaling responses to Pneumocystis carinii β-glucans. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00811-23
BibTeX
@article{Kottom2024,
author = {Kottom, Theodore J and Carmona, Eva M and Limper, Andrew H},
title = {Targeting host tyrosine kinase receptor EphA2 signaling via small-molecule ALW-II-41-27 inhibits macrophage pro-inflammatory signaling responses to Pneumocystis carinii β-glucans},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.00811-23}
}
EUVIMED